ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신부전증 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 급성 신장 손상(AKI)의 유병률 증가, 가정 기반 치료 옵션의 채택 증가, 의료비 지출의 급증, 연구개발 투자의 확대 등이 있습니다.
고혈압과 당뇨병의 유병률 상승은 앞으로 수년간 신부전증 시장의 성장을 견인할 것으로 예측됩니다. 고혈압은 흉터를 유발하고 여과 능력의 저하에 의해 신장혈관에 데미지를 주고, 당뇨병은 혈당의 상승에 의해 신장 혈관이 두꺼워지고 과로하게 만듭니다. 5월 영국 정부기관인 국민보건서비스(NHS)는 2023년 12월 남동부의 고혈압 진단 환자 수가 7만 1,120명 증가했으며 2022년 12월에 비해 5.4% 증가했다고 덧붙였습니다. 영국을 거점으로 하는 자선 단체인 영국 당뇨병 협회는 2023년 4월, 영국에서 430만명이 당뇨병이라고 진단되었다고 발표했습니다. 그 결과, 고혈압과 당뇨병의 유병률 증가가 신부전증 시장의 확대에 박차를 가하고 있습니다.
신부전증 시장의 주요 기업은 당뇨병 및 만성 신장병(CKD) 환자의 신장 및 심혈관 합병증을 다루기 때문에 글루카곤-유사 펩티드-1 수용체 작용제(GLP-1 RA)의 개발에 주력하고 있습니다. 이 약은 글루코오스 컨트롤을 강화하고 염증을 억제하고 신장에서의 산화 스트레스를 저하시킴으로써 신부전증의 진행을 지연시킵니다. Nordisk사는 2형 당뇨병과 CKD를 가진 성인에서 신장병의 진행, 신부전증, 심혈관사 위험을 줄이는 오젠픽(세마글루티드)의 FDA(식품의약국) 승인을 취득했습니다. RA의 역할이 높아지고 있음을 강조하는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 신부전증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계 신부전증 시장 : 성장률 분석
세계 신부전증 시장 실적 : 규모와 성장, 2019-2024
세계 신부전증 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 신부전증 전체 시장 규모(TAM)
제6장 시장 세분화
세계 신부전증 시장 : 치료유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
의약품
투석
신장 이식
기타 치료의 유형
세계 신부전증 시장 : 질병 스테이지별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
만성 신장병(CKD)의 스테이지
말기신질환(ESRD)
세계 신부전증 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계 신부전증 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
투석 센터
병원 및 진료소
조사·학술 기관
세계 신부전증 시장 : 의약품유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
안지오텐신 전환효소(ACE) 억제제
안지오텐신 II 수용체 길항제(ARB)
이뇨제
적혈구 조혈 자극 인자 제제(ESA)
인산 결합제
중탄산나트륨
세계 신부전증 시장 : 투석유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
혈액투석
복막 투석
재택 투석
지속적 신 대체요법(CRRT)
세계 신부전증 시장 : 신장 이식유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
생체신 이식
뇌사 기증자에 의한 신장 이식
신장 이식 면역 억제 요법
세계 신부전증 시장 : 기타 치료 유형의별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
라이프 스타일과 식생활 개선
줄기세포요법
유전자 치료
제7장 지역별, 국가별 분석
세계 신부전증 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계 신부전증 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
신부전증 시장 : 경쟁 구도
신부전증 시장 : 기업 프로파일
Kaiser Permanente Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
Medtronic plc
Amgen Inc.
Asahi Kasei Medical Co. Ltd.
Fujifilm Holdings Corporation
Fresenius Medical Care
Toray Industries Inc.
Baxter International Inc.
Boehringer Ingelheim
DaVita Inc.
Eisai Co. Ltd.
Nipro Corporation
Biocon Limited
HemoCue AB
Rockwell Medical
Mitsubishi Tanabe Pharma Corporation
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
신부전증 시장(2029년) : 새로운 기회를 제공하는 국가
신부전증 시장(2029년) : 새로운 기회를 제공하는 부문
신부전증 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Renal insufficiency refers to the decreased ability of the kidneys to filter waste products and maintain fluid and electrolyte balance in the body. It can result from chronic conditions such as diabetes, hypertension, or acute kidney injury, leading to toxin buildup in the blood. If left untreated, renal insufficiency may progress to chronic kidney disease (CKD) or kidney failure, necessitating dialysis or transplantation.
The primary treatment options for renal insufficiency include medications, dialysis, kidney transplantation, and other interventions. Medications help manage symptoms, slow disease progression, and address complications such as high blood pressure, diabetes, and anemia. The condition progresses through different stages, including chronic kidney disease (CKD) stages and end-stage renal disease (ESRD). Treatment is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including dialysis centers, hospitals, clinics, and research and academic institutes.
The renal insufficiency market research report is one of a series of new reports from The Business Research Company that provides renal insufficiency market statistics, including renal insufficiency industry global market size, regional shares, competitors with a renal insufficiency market share, detailed renal insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the renal insufficiency industry. This renal insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The renal insufficiency market size has grown rapidly in recent years. It will grow from $10.87 billion in 2024 to $12.14 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to the rising cases of high blood pressure and diabetes, the increasing prevalence of chronic kidney disease (CKD), a higher occurrence of urinary tract obstructions, an aging population, and greater awareness and education about kidney health.
The renal insufficiency market size is expected to see rapid growth in the next few years. It will grow to $18.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to the rising prevalence of acute kidney injuries (AKI), increasing adoption of home-based treatment options, a surge in healthcare expenditure, and greater investments in research and development. Key trends include advancements in medical technology, innovations in treatment options, the integration of personalized medicine, improvements in dialysis technology, and the development of new and innovative medications.
The rising prevalence of high blood pressure and diabetes is expected to drive the growth of the renal insufficiency market in the coming years. These conditions are influenced by factors such as poor diet, lack of physical activity, obesity, genetic predisposition, and an aging population. High blood pressure damages kidney blood vessels by causing scarring and reducing filtration capacity, while diabetes leads to thickened and overworked kidney vessels due to elevated blood sugar levels. Both conditions accelerate kidney damage, ultimately resulting in renal insufficiency. For example, in May 2024, the National Health Service (NHS), a UK-based government agency, reported that the number of high blood pressure diagnoses in the South East increased by 71,120 patients in December 2023, marking a 5.4% rise compared to December 2022. Additionally, in April 2023, the British Diabetic Association, a UK-based charity organization, stated that 4.3 million people in the UK had been diagnosed with diabetes. Consequently, the increasing prevalence of high blood pressure and diabetes is fueling the expansion of the renal insufficiency market.
Leading companies in the renal insufficiency market are focusing on the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address renal and cardiovascular complications in patients with diabetes and chronic kidney disease (CKD). These medications enhance glucose control, reduce inflammation, and lower oxidative stress in the kidneys, thereby slowing the progression of renal insufficiency. For example, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration (FDA) approval for Ozempic (semaglutide) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD. This approval underscores the growing role of GLP-1 RAs in providing a dual approach to managing diabetes and renal insufficiency, addressing key unmet medical needs for patients with progressive CKD.
In February 2023, AstraZeneca PLC, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition enhances AstraZeneca's cardiorenal portfolio by incorporating baxdrostat (CIN-107), an aldosterone synthase inhibitor designed to lower blood pressure in patients with treatment-resistant hypertension. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company focused on developing treatments for individuals with moderate to severe renal impairment or kidney failure.
Major players in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, and Sorin Group.
North America was the largest region in the renal insufficiency market in 2024. The regions covered in renal insufficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the renal insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The renal insufficiency market consists of sales of dialysis equipment, renal replacement therapies, kidney transplantation services, and pharmaceutical treatments for managing kidney function. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Renal Insufficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on renal insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for renal insufficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renal insufficiency market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Medications; Dialysis; Kidney Transplantation; Other Treatment Types
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Renal Insufficiency Market Characteristics
3. Renal Insufficiency Market Trends And Strategies
4. Renal Insufficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Renal Insufficiency Growth Analysis And Strategic Analysis Framework
5.1. Global Renal Insufficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Renal Insufficiency Market Growth Rate Analysis
5.4. Global Renal Insufficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Renal Insufficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Renal Insufficiency Total Addressable Market (TAM)
6. Renal Insufficiency Market Segmentation
6.1. Global Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Dialysis
Kidney Transplantation
Other Treatment Types
6.2. Global Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Kidney Disease (CKD) Stages
End-Stage Renal Disease (ESRD)
6.3. Global Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Renal Insufficiency Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dialysis Centers
Hospital And Clinics
Research And Academic Institutes
6.5. Global Renal Insufficiency Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Diuretics
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Sodium Bicarbonate
6.6. Global Renal Insufficiency Market, Sub-Segmentation Of Dialysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hemodialysis
Peritoneal Dialysis
Home Dialysis
Continuous Renal Replacement Therapy (CRRT)
6.7. Global Renal Insufficiency Market, Sub-Segmentation Of Kidney Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Living Donor Kidney Transplant
Deceased Donor Kidney Transplant
Kidney Transplant Immunosuppressive Therapy
6.8. Global Renal Insufficiency Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lifestyle And Dietary Modifications
Stem Cell Therapy
Gene Therapy
7. Renal Insufficiency Market Regional And Country Analysis
7.1. Global Renal Insufficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Renal Insufficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
